OBJECTIVE: To rapidly evaluate the efficacy

safety and economy of propofol in gastrointestinal endoscopy

so as to provide evidence-based reference for its clinical rational application. METHODS: Pub Med

EMBase

the Cochrane Library

CNKI

Wanfang database

CBM and the websites and databases related to health technology assessment（ HTA） were systematically searched. HTA reports

systematic review/Meta-analysis and pharmacoeconomic studies related to propofol and placebo or other traditional sedations for gastrointestinal endoscopy were included. According to the inclusion and exclusion criteria

two reviewers independently screened the literature

extracted and summarized the data

evaluated the literature with assessment of multiple systematic reviews（ AMSTAR）and consolidated health economic evaluation reporting standards（ CHEERS）

and analyzed the research results with qualitative description method. RESULTS: Totally 12 systematic reviews/Meta-analysis and 2 pharmacoeconomic studies were included

and no relevant HTA report was retrieved. The results showed that compared with the control group

propofol used in gastrointestinal endoscopy had earlier discharge time

faster recovery

higher satisfaction rate and did not increase the risk of cardiopulmonary adverse drug reactions

but it would increase the injection site pain

and the economic cost was higher. CONCLUSIONS: Propofol has good efficacy and safety in painless gastrointestinal endoscopy

yet its economic performance is poor

which needs to be further demonstrated.